menu
    • menu
    [{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0.12,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Flare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Flare Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Caris Life Sciences \/ Flare Therapeutics"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

    Menu

    3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Flare Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Flare Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanc...

                            Details : FX-909 is a highly potent and selective inhibitor of PPARG and has demonstrated tumor eradication in preclinical animal models of urothelial cancer at low oral doses.

                            Brand Name : FX-909

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2023

                            Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Caris Life Sciences

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Caris Life Sciences

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Flare Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare...

                            Details : The collaboration focuses to accelerate precision medicine approaches across five of Flare's programs, including its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG, into clinical trials through advanced molecular prof...

                            Brand Name : FX-909

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 13, 2023

                            Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Flare Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Flare Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Flare Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : GordonMD Global Investments

                            Deal Size : $123.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing

                            Details : The net proceeds will be used to support the advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare's platform and pipeline of novel transcription factor targets in oncology.

                            Brand Name : FX-909

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 22, 2023

                            Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : GordonMD Global Investments

                            Deal Size : $123.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Flare Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Flare Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Supp...

                            Details : Flare is advancing a novel PPARG inhibitor through Investigational New Drug (IND)-enabling studies and expects to initiate its Phase 1 clinical trial for FX-909 in 2023 in individuals with locally advanced or metastatic UC.

                            Brand Name : FX-909

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2022

                            Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth